HK Stock Market Move | XUANZHUBIO-B(02575) continues to rise by more than 11%, setting a new record high since its IPO, with an increase of over 190% from its offer price.

XUANZHUBIO-B (02575) rose by over 11% again, hitting a high of 33.96 Hong Kong dollars during the trading session, setting a new high since the IPO, up over 190% from the offer price of 11.6 Hong Kong dollars. As of the time of writing, it is up 11.03% at 32.2 Hong Kong dollars, with a turnover of 54.043 million Hong Kong dollars. Public information shows that Xuanzhu Bio is backed by the Hong Kong-listed company SIHUAN PHARM and is a company with two research and development systems for small molecule drugs and large molecule biopharmaceuticals, driven by innovation, affiliated with SINO BIOPHARM. As of September 26, 2025, the company has successfully developed four candidate drugs, with over 10 drug assets actively in development, covering digestive system diseases, tumors, and non-alcoholic fatty liver disease (NASH). The company currently has three commercial products: the duodenal ulcer drug omeprazole sodium, the breast cancer drug pyrotinib, and the non-small cell lung cancer drug alunbrig, approved in 2023 and 2025 respectively. Huafu Securities believes that Chinese innovative drugs are undergoing "quantitative changes leading to qualitative changes", optimistic about the industrial trend of innovative drugs in the next 5-10 years, with BD going global, continuous data catalysis, and new product sales volume set to drive the rise of innovative drugs.